A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The objective of this study was to investigate whether quetiapine, when compared with placebo, can speed the onset of action and improve the quality of response to fluoxetine treatment in patients suffering from major depressive disorder. A total of 114 patients with major depressive disorder were enrolled in an 8-week treatment study. Patients were initiated on a course of fluoxetine treatment and randomized to quetiapine or placebo. Quetiapine was flexibly dosed starting at 25 mg to a maximum of 100 mg daily. Mixed-effects regression showed that quetiapine plus fluoxetine did not achieve 50% reduction in the Montgomery-Asberg Depression Rating Scale score or improvement in Hamilton Anxiety Scale, Clinical Global Improvement (CGI)-Severity, and CGI-Improvement scores sooner than the fluoxetine plus placebo group; however both groups improved in all scores over time. Mixed-effects linear regression of insomnia scores showed that the quetiapine plus fluoxetine group improved significantly more rapidly compared with the fluoxetine plus placebo group. The study indicates that quetiapine plus fluoxetine did not achieve a reduction in the Montgomery-Asberg Depression Rating Scale score or improvement in Hamilton Anxiety Scale or CGI scores from baseline sooner than the fluoxetine plus placebo group. The combination of quetiapine and fluoxetine, however, improved sleep over fluoxetine alone over the first few weeks of treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380 · cited 1×
“Most augmentation trials have been conducted in patients with treatment-resistant depression (TRD), which is defined, at a minimum, as failure of an adequate trial of at least two antidepressant medications (Fava, 2003).”
BackgroundTaylor, M. J., Freemantle, N., Geddes, J. R., & Bhagwagar, Z. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.11.1217 · Cited by 406 · cited 1×
“However, there has been recent evidence that the ‘delayed-onset hypothesis’ may be inaccurate, and that there is a noticeable response within the first week of initiation of treatment (Katz et al., 2004; Posternak and Zimmerman, 2005; Taylor et al., 2006).”
BackgroundMarek, G. J., Carpenter, L. L., McDougle, C. J., & Price, L. H. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300057 · Cited by 275 · cited 2×
“sleep patterns and sleep structure or, perhaps, acting synergistically on 5-HT reuptake inhibition (Marek et al., 2003; Devarajan et al., 2006), or in part through its antagonistic effects on histamine receptors.”
BackgroundKatz, M. M., Tekell, J. L., Bowden, C. L., Brannan, S., Houston, J. P., Berman, N., & Frazer, A. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300341 · Cited by 252 · cited 1×
“However, there has been recent evidence that the ‘delayed-onset hypothesis’ may be inaccurate, and that there is a noticeable response within the first week of initiation of treatment (Katz et al., 2004; Posternak and Zimmerman, 2005; Taylor et al., 2006).”
BackgroundIs there a delay in the antidepressant effect? A meta-analysis
Posternak, M. A., & Zimmerman, M. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0201 · Cited by 250 · cited 1×
“However, there has been recent evidence that the ‘delayed-onset hypothesis’ may be inaccurate, and that there is a noticeable response within the first week of initiation of treatment (Katz et al., 2004; Posternak and Zimmerman, 2005; Taylor et al., 2006).”
BackgroundCrossley, N. A., & Bauer, M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0617 · Cited by 246
Montgomery, S. A., Huusom, A. K. T., & Bothmer, J. (2004) · Neuropsychobiology · doi:10.1159/000078225 · Cited by 168
Chouinard, G., & Chouinard, V.-A. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000112883 · Cited by 168 · cited 1×
“Finally, it is possible that genetic differences in the metabolism of quetiapine may account for the lack of significant findings, as we did not measure blood levels of the drug during the study (Chouinard and Chouinard, 2008).”
ResultMcIntyre, A., Gendron, A., & McIntyre, A. (2007) · Depression and Anxiety · doi:10.1002/da.20275 · Cited by 145
Hirschfeld, R. M. A., Weisler, R. H., Raines, S. R., Macfadden, W., & BOLDER Study Group (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0304 · Cited by 116 · cited 1×
“Major advantages of quetiapine include potential anxiolytic properties, as supported in studies of patients with depression and comorbid anxiety (Hirschfeld et al., 2006; McIntyre et al., 2007).”
Background
Cited by
Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
“…as weight gain and prolactin increase (studies included: Shelton et al. 2001, 2005; Andersen et al. 2005; Corya et al. 2006; Berman et al. 2007; Doree et al. 2007; Mahmoud et al. 2007; McIntyre et al. 2007; Thase et al. 2007; Garakani et al. 2008; Keitner et al. 2009; Nelson and Papakostas 2009).”
BackgroundConnolly, K. R., & Thase, M. E. (2011) · Drugs · doi:10.2165/11587620-000000000-00000 · Cited by 462
Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery
Atkin, T., Comai, S., & Gobbi, G. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014381 · Cited by 391
Psychiatric Disorders and Sleep Issues
Sutton, E. L. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.06.009 · Cited by 119
Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines
Taylor, R. W., Marwood, L., Oprea, E., DeAngel, V., Mather, S., Valentini, B., Zahn, R., Young, A. H., & Cleare, A. J. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa033 · Cited by 76
Metadata
- Authors
- Garakani, A., Martinez, J. M., Marcus, S., Weaver, J., Rickels, K., Fava, M., & Hirschowitz, J.
- Venue
- International Clinical Psychopharmacology
- Published
- 2008-09
- Volume
- 23
- Issue
- 5
- Pages
- 269-275
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2025525296
- Cited by
- 39
- References
- 11
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. https://app.cochat.ai/papers/10.1097/yic.0b013e328301a74c
- The paper
- Garakani, A., Martinez, J. M., Marcus, S., Weaver, J., Rickels, K., Fava, M., & Hirschowitz, J. (2008). A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0b013e328301a74c
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.